Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that eight abstracts, including four that are late-breaking, will be presented on Epidiolex® (cannabidiol) at the American Epilepsy Society (AES ...
Dublin, Feb. 14, 2025 (GLOBE NEWSWIRE) -- The "Cannabidiol (CAS 13956-29-1) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ...
Full-spectrum CBD tinctures are the foundation of Lazarus Naturals’ product lineup. A classic yet flexible option for adding ...
GW’s cannabis-based medicine rescheduled following approval by the European Medicines Agency (EMA) and an independent assessment by the Advisory Council on the Misuse of Drugs (ACMD) In its ...
GW Pharmaceuticals now part of Jazz Pharmaceuticals plc announces that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved a new indication for GW's cannabidiol as an ...
CBD has become one of the most popular health supplements in the UK over the past decade. Among the most popular of all CBD products are sublingual CBD oils. Sublingual CBD tinctures have ...
GW Pharmaceuticals PLC (NASDAQ: GWPH) took a big step forward for the development of its cannabidiol in the United Kingdom. The company announced that the U.K. Home Office has reclassified Epidyolex ...
CHICAGO, June 11, 2025 /PRNewswire/ -- The Global Cannabidiol Market size is projected to be valued at USD 9.14 billion in 2024 and reach USD 22.05 billion by 2030, growing at a CAGR of 15.8% ...
LONDON (Alliance News) - GW Pharmaceuticals PLC Tuesday said it received positive top line results from its Phase 2a placebo-controlled clinical trial of cannabidiol in patients with schizophrenia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback